| Symbol | ESPR |
|---|---|
| Name | ESPERION THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3891 RANCHERO DRIVE,SUITE 150, ANN ARBOR, Michigan, 48108, United States |
| Telephone | +1 734 887-3903 |
| Fax | — |
| — | |
| Website | https://www.esperion.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001434868 |
| Description | Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Additional info from NASDAQ: |
2026-05-04 17:05
New Form DEFA14A - Esperion Therapeutics, Inc. <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0001104659-26-054868 <b>Size:</b> 21 KB
Read more
2026-05-04 15:48
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
Read more
2026-05-01 17:00
New Form DEFA14A - Esperion Therapeutics, Inc. <b>Filed:</b> 2026-05-01 <b>AccNo:</b> 0001104659-26-054100 <b>Size:</b> 25 KB
Read more
2026-05-01 15:30
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Read more
2026-05-01 13:41
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Read more
2026-04-22 16:45
New Form SCHEDULE 13G - Esperion Therapeutics, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0000814133-26-000048 <b>Size:</b> 7 KB
Read more
2026-04-16 17:13
New Form DEFA14A - Esperion Therapeutics, Inc. <b>Filed:</b> 2026-04-16 <b>AccNo:</b> 0001628280-26-025501 <b>Size:</b> 381 KB
Read more
2026-04-16 17:12
New Form DEF 14A - Esperion Therapeutics, Inc. <b>Filed:</b> 2026-04-16 <b>AccNo:</b> 0001628280-26-025499 <b>Size:</b> 3 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06021951 | Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and B… | Phase4 | Healthy Lactating Women | Completed | 2023-08-04 | 2024-03-22 | ClinicalTrials.gov |
| NCT06300450 | Randomized Controlled Trial of Alert-Based Computerized Decision Support for Pa… | Na | Peripheral Artery Disease | Recruiting | 2023-03-01 | 2026-07-30 | ClinicalTrials.gov |
| NCT05694260 | A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (H… | Phase2 | Hypercholesterolemia | Completed | 2023-01-12 | 2025-06-04 | ClinicalTrials.gov |
| NCT05263778 | Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in… | Phase4 | Cardiovascular Diseases | Unknown | 2022-03-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT05103254 | Bempedoic Acid Pregnancy Surveillance Program | — | Pregnancy | Recruiting | 2021-09-01 | 2032-05-01 | ClinicalTrials.gov |
| NCT03531905 | Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With … | Phase2 | Diabetes | Completed | 2018-05-09 | 2019-06-18 | ClinicalTrials.gov |
| NCT03337308 | A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fix… | Phase3 | Hyperlipidemias | Completed | 2017-10-23 | 2018-07-18 | ClinicalTrials.gov |
| NCT03193047 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When A… | Phase2 | Hypercholesterolemia | Completed | 2017-04-07 | 2018-02-19 | ClinicalTrials.gov |
| NCT03067441 | Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmon… | Phase3 | Hypercholesterolemia | Completed | 2017-02-03 | 2019-11-05 | ClinicalTrials.gov |
| NCT03051100 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezeti… | Phase2 | Hypercholesterolemia | Completed | 2017-01-19 | 2017-07-05 | ClinicalTrials.gov |
| NCT02993406 | Evaluation of Major Cardiovascular Events in Participants With, or at High Risk… | Phase3 | Cardiovascular Diseases | Completed | 2016-12-22 | 2022-11-07 | ClinicalTrials.gov |
| NCT03001076 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to… | Phase3 | Hypercholesterolemia | Completed | 2016-11-29 | 2018-02-12 | ClinicalTrials.gov |
| NCT02991118 | Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With … | Phase3 | Hypercholesterolemia | Completed | 2016-11-18 | 2018-08-22 | ClinicalTrials.gov |
| NCT02988115 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients … | Phase3 | Hypercholesterolemia | Completed | 2016-11-16 | 2018-03-16 | ClinicalTrials.gov |
| NCT02666664 | Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patien… | Phase3 | Hypercholesterolemia | Completed | 2016-01-21 | 2018-03-28 | ClinicalTrials.gov |
| NCT02659397 | A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To … | Phase2 | Hyperlipidemia | Completed | 2015-12-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02178098 | Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertensi… | Phase2 | Hypercholesterolemia | Completed | 2014-06-16 | 2015-05-22 | ClinicalTrials.gov |
| NCT02072161 | Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy | Phase2 | Hypercholesterolemia | Completed | 2014-03-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02044627 | Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Ex… | Phase1 | Hyperlipidemia | Completed | 2013-12-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01941836 | Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic … | Phase2 | Hypercholesterolemia | Completed | 2013-09-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01779453 | A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-100… | Phase2 | Hypercholesterolemia | Completed | 2012-12-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01751984 | A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Into… | Phase2 | Hypercholesterolemia | Completed | 2012-10-04 | 2013-05-01 | ClinicalTrials.gov |
| NCT01607294 | A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjec… | Phase2 | Hyperlipidemia | Completed | 2012-04-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01485146 | A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects | Phase1 | Safety Evaluation of Escalating Doses | Completed | 2011-10-25 | 2012-01-25 | ClinicalTrials.gov |
| NCT01262638 | A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated… | Phase2 | Dyslipidemia | Completed | 2010-12-01 | 2011-08-23 | ClinicalTrials.gov |
| NCT01105598 | A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia | Phase1 | Mild Dyslipidemia | Completed | 2010-04-20 | 2010-10-02 | ClinicalTrials.gov |
Total clinical trials: 26
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| [14C-ETC-1002] | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT02044627 |
| ETC-1002 | Other | Phase PHASE1 | Safety Evaluation of Escalating Doses | COMPLETED | NCT01485146 |
| ETC-1002 or placebo | Other | Phase PHASE1 | Mild Dyslipidemia | COMPLETED | NCT01105598 |
| Placebo | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT02659397 |
| Atorvastatin | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT02659397 |
| ETC-1002 | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT02659397 |
| Statin Therapy | Drug | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT02072161 |
| Placebo | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT02072161 |
| ETC-1002 | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT02072161 |
| Ezetimibe | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT01941836 |
| ETC-1002 | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT01941836 |
| Atorvastatin | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT01779453 |
| Placebo | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT01779453 |
| ETC-1002 | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT01779453 |
| Placebo | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01607294 |
| ETC-1002 | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT01607294 |
| evolocumab | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03193047 |
| placebo | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03193047 |
| bempedoic acid 180mg | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03193047 |
| Placebo | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03051100 |
| Atorvastatin 20mg | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03051100 |
| Ezetimibe 10mg | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03051100 |
| Bempedoic acid 180mg | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03051100 |
| placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02988115 |
| bempedoic acid | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02988115 |
| Placebos | Other | Phase PHASE3 | Hyperlipidemias | COMPLETED | NCT03337308 |
| Ezetimibe | Other | Phase PHASE3 | Hyperlipidemias | COMPLETED | NCT03337308 |
| Bempedoic Acid | Other | Phase PHASE3 | Hyperlipidemias | COMPLETED | NCT03337308 |
| Bempedoic Acid + Ezetimibe Fixed-Dose Combination | Other | Phase PHASE3 | Hyperlipidemias | COMPLETED | NCT03337308 |
| Placebo oral capsule | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT03531905 |
| Placebo Oral Tablet | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT03531905 |
| Ezetimibe 10 mg Oral Tablet | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT03531905 |
| Bempedoic acid + Ezetimibe FDC Oral Tablet | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT03531905 |
| placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02991118 |
| bempedoic acid | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02991118 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03001076 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03001076 |
| Bempedoic acid | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03001076 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02666664 |
| ETC-1002 | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02666664 |
| bempedoic acid | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03067441 |
| Placebo | Other | Phase PHASE2 | Dyslipidemia | COMPLETED | NCT01262638 |
| ETC-1002 | Other | Phase PHASE2 | Dyslipidemia | COMPLETED | NCT01262638 |
| Placebo | Other | Phase PHASE4 | Cardiovascular Diseases | UNKNOWN | NCT05263778 |
| Bempedoic Acid / Ezetimibe Oral Tablet | Other | Phase PHASE4 | Cardiovascular Diseases | UNKNOWN | NCT05263778 |
| Placebo | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT01751984 |
| ETC-1002 | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT01751984 |
| Placebo | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT02178098 |
| ETC-1002 | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT02178098 |
| Matching placebo tablet | Other | Phase PHASE3 | Cardiovascular Diseases | COMPLETED | NCT02993406 |
| Bempedoic acid 180 mg tablet | Other | Phase PHASE3 | Cardiovascular Diseases | COMPLETED | NCT02993406 |
| Bempedoic Acid / Ezetimibe | Other | Preclinical | Pregnancy | RECRUITING | NCT05103254 |
| Bempedoic Acid | Other | Preclinical | Pregnancy | RECRUITING | NCT05103254 |
| Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet | Other | Phase PHASE4 | Healthy Lactating Women | COMPLETED | NCT06021951 |
| Bempedoic Acid 180 MG Oral Tablet | Other | Phase PHASE4 | Healthy Lactating Women | COMPLETED | NCT06021951 |
| Bempedoic acid | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT05694260 |
| Computer Alert | Other | Approved | Peripheral Artery Disease | RECRUITING | NCT06300450 |
| Computer Alert | BEHAVIORAL | Approved | Peripheral Artery Disease | RECRUITING | NCT06300450 |
| Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet | DRUG | Phase PHASE4 | Healthy Lactating Women | COMPLETED | NCT06021951 |
| Bempedoic Acid 180 MG Oral Tablet | DRUG | Phase PHASE4 | Healthy Lactating Women | COMPLETED | NCT06021951 |
| Bempedoic Acid / Ezetimibe Oral Tablet | DRUG | Phase PHASE4 | Cardiovascular Diseases | UNKNOWN | NCT05263778 |
| Bempedoic Acid / Ezetimibe | DRUG | Preclinical | Pregnancy | RECRUITING | NCT05103254 |
| Placebo oral capsule | DRUG | Phase PHASE2 | Diabetes | COMPLETED | NCT03531905 |
| Placebo Oral Tablet | DRUG | Phase PHASE2 | Diabetes | COMPLETED | NCT03531905 |
| Ezetimibe 10 mg Oral Tablet | DRUG | Phase PHASE2 | Diabetes | COMPLETED | NCT03531905 |
| Bempedoic acid + Ezetimibe FDC Oral Tablet | DRUG | Phase PHASE2 | Diabetes | COMPLETED | NCT03531905 |
| Placebos | DRUG | Phase PHASE3 | Hyperlipidemias | COMPLETED | NCT03337308 |
| Bempedoic Acid | DRUG | Preclinical | Pregnancy | RECRUITING | NCT05103254 |
| evolocumab | DRUG | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03193047 |
| bempedoic acid 180mg | DRUG | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03193047 |
| Atorvastatin 20mg | DRUG | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03051100 |
| Ezetimibe 10mg | DRUG | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03051100 |
| Bempedoic acid 180mg | DRUG | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03051100 |
| Bempedoic acid | DRUG | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT05694260 |
| Matching placebo tablet | DRUG | Phase PHASE3 | Cardiovascular Diseases | COMPLETED | NCT02993406 |
| Bempedoic acid 180 mg tablet | DRUG | Phase PHASE3 | Cardiovascular Diseases | COMPLETED | NCT02993406 |
| placebo | OTHER | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03193047 |
| bempedoic acid | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03067441 |
| Statin Therapy | DRUG | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT02072161 |
| [14C-ETC-1002] | DRUG | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT02044627 |
| Ezetimibe | DRUG | Phase PHASE3 | Hyperlipidemias | COMPLETED | NCT03337308 |
| Atorvastatin | DRUG | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT02659397 |
| Placebo | DRUG | Phase PHASE4 | Cardiovascular Diseases | UNKNOWN | NCT05263778 |
| ETC-1002 | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02666664 |
| ETC-1002 or placebo | DRUG | Phase PHASE1 | Mild Dyslipidemia | COMPLETED | NCT01105598 |
Total products: 85